Atlas Trials

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Clinical trial NCT03198026 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03198026
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Nodal Marginal Zone LymphomaAnn Abor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Nodal Marginal Zone LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Nodal Marginal Zone Lymphoma
Start date
2018-02-20
Primary completion
2023-10-24
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.